Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two Adjuvants

NCT01081847 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Malaria, Vivax

Interventions

DRUG: Peptides (N,R&C) formulated in Montanide ISA 720
DRUG: Peptides (N,R&C) formulated in Montanide ISA 51
DRUG: Peptides (N,R&C) formulated in Montanide ISA 720
DRUG: Peptides (N,R&C) formulated in Montanide ISA 51
OTHER: Placebo

Sponsor

Malaria Vaccine and Drug Development Center

Collaborators

[object Object]
[object Object]